Love. It is something you express to your children. You kiss boo-boos, you give hugs after a long day and you hold their hands just a little bit longer than necessary when crossing the street. You also probably tell them that you love them every chance you get. Love is something your children will show and tell you in reciprocation more and more as they grow older (although the law of diminishing returns may apply in the teen years). Displays of affection can do wonders to how you feel, but for the mother and father of an autistic child, it may seem like they can never give that gift to their child—or receive it in return.
An avoidance of social touch and an inability to understand or take part in verbal and nonverbal social communication are just two of autism's characteristics, which are often grouped into bigger areas of concern like overall behavior, social interactions, language development and sensory sensitivity. Bearing a child with autism is a growing concern for many parents as the number of people it affects has risen over the years. While this increase may be contributed to how autism is diagnosed, it could be that other factors are increasing its prevalence. As of now, autism affects one in 37 boys and one in 59 children in general. Current therapies and medications for autism are designed to treat some of the specific symptoms of the condition, but scientists have yet to figure out how to move a child off the spectrum.
But all this could change as Dr. Joanne Kurtzberg at Duke University Medical Center and other researchers are bringing new hope to the treatment of autism.
The video above was taken at the child's initial and six-month evaluations. It contains two videos, each offered from two angles. The first video shows the child before his cord blood transfusion. He shows some of the typical symptoms of autism including frequent repetitive behaviors, absence of simple, functional toy play and avoidance of social interaction, touch and intimacy with his father. The second video shows that same little boy six months later. The first thing you'll notice is that he is in his father's arms. This is in complete contrast to the lack of social touch the child displayed in the first video. He also is no longer displaying the use of repetitive behaviors—except for the continued engagement in social interactions and toy play that he is now able to enjoy with his father.
Even more encouraging is the before-and-after video one year post-cord blood therapy for one little boy with autism. At first, we see he can express few words and limited vocalizations. He uses minimal physical gestures, engages in limited physical interaction and doesn't make eye contact with the researcher. In the next video, of the one-year evaluation, we see a dramatically different version of that same little boy. He is expressing himself with full sentences and gestures, conducting imaginary play and shows increased emotional response including sustained eye contact. In that one year, this little boy's IQ went from 54 to 82, and his language score rose from 62 to 97.
Dr. Kurtzberg's Studies
In June 2014, Duke University Medicine was awarded $15 million to support an innovative research program to explore the use of umbilical cord blood cells to treat autism, stroke, cerebral palsy and related brain disorders. The various phases of a clinical trial take years to complete, but in early 2017, Duke University released the results from its preliminary, phase I study on the safety of treating children with autism with an intravenous infusion of their own umbilical cord blood.
The results are exciting, enabling them to move to a full-blown double-blind, placebo-controlled phase two study. If the results follow what they have been seeing so far, it will spawn a better new way to treat autism.
In the phase I study, researchers found that among 25 children ages 2–5, more than two-thirds appeared to show improvements in speech, socialization, and eye contact as reported by parents and assessed by researchers.
“We are cautiously optimistic about these early findings,” said Duke Pediatric Bone Marrow Transplant Specialist Joanne Kurtzberg, MD, who is a principal investigator of the study. Dr. Kurtzberg is also the medical director for Cryo-Cell International.
Its phase one trial included two evaluations: one at six months and another at 12 months. At the six-month evaluations, between 60 and 70 percent of the children showed improvements in aspects of their autism including sensory behaviors, receptive and expressive communication, repetitive and manipulative behaviors, and social withdrawal.
Dr. Chez’s Study
Another study run by the Sutter Institute of Medical Research explored the use of stem cells from umbilical cord blood to improve language and behavior in children with autism. Twenty-nine children with autism and ranging in age from two years to seven years received an infusion of their own cord blood stem cells stored at birth. Afterwards, the participants were regularly tested for a year using a variety of psychological and cognitive assessment tools. Sixty percent of the parents of the children who participated in the study said they saw moderate to significant improvements, especially in language and social skills.
Dr. Chez with a young autistic girl
The trial’s principal investigator, Dr. Michael Chez, director of Pediatric Neurology at the Sutter Institute, reports that “the results of this study indicate that cord blood stem cells may offer ways to modulate or repair the immune systems of these patients with autism, and in doing so, improve language and some behavior in some children. More work is needed to prove this, but for a small placebo-controlled pilot study, this is a very good outcome.”
Dr. Chez also believes that any positive effects seen after the treatment would probably not wear off over time.
“When children with autism gain a new skill, it’s like making a new connection (in the brain). The brain shouldn’t deteriorate unless it is a degenerative disease,” he said.
One of the first clinical trials to look at cord blood as a treatment for autism was completed in August 2013 in China. Thirty-seven children with autism were divided into three groups: 14 subjects received cord blood mononuclear cells (CBMNC) transplantation and rehabilitation therapy; nine subjects received both CBMNC and umbilical cord–derived mesenchymal stem cell (UCMSC) transplantation and rehabilitation therapy; and 14 subjects received only rehabilitation therapy. The results showed that transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone.
CNN posted a video of one family who took part in the clinical trial at Duke University and saw encouraging outcomes in their young daughter, Gracie.
Gracie displayed many of the traits of autism including avoidance of social touch and verbal and nonverbal communication, repetition of actions, and overall behaviorial problems such as trantrums, outbursts, and public fits. She was diagnosed with mild to moderate autism a little after her second birthday, but her parents, Gina and Wade Gregory, say caring for her consumed about 75% of their day.
It is around this time that Gracie's parents first heard about a trial using cold blood in the treatment of autism. After taking part in this phase I trial, Gracie has never been the same.
On a scale of 1 to 10, Gina and Wade say her improvements have been around an 8 or 9. They says her autism now affects only 10% of their day and that Gracie's trantrums have gotten much better, she shows more affection, and she can better handle stressful social situations. Up until this change in Gracie's behavior, she did not seem to fit in any specialized school programs, where, today, Gracie is able to attend—and thrive in—"regular" school.
"We will say we don't think it's cured her. You still see some of the small idiosyncrasies that she does have," said Wade. "But again, I think it's supercharged her learning curve. It's pushed her to do things she normally wouldn't do."
"She got better, and we're just thankful for that," added Gina.
How Cord Blood Treats Autism
Cord blood has the ability to cross the blood–brain barrier and differentiate into neurons and other brain cells. There are a few schools of thought on how cord blood can repair brain trauma or neurodegenerative disorders:
- The transplanted stem cells directly replace dead or dying cells.
- The transplanted stem cells secret growth factors that indirectly rescue the injured tissue.
- The transplanted stem cells build a “biobridge” that connects the healthy section of the brain and the damaged section of the brain to facilitate the transport of new neural stem cells to the area in need of repair.
Current Clinical Trials
Duke University Medical Center received permission to expand access to cord blood therapies for brain disorders including autism and cerebral palsy, attracting the attention of many parents with stored cord blood. The clinical trial is open to children who have their own cord blood stored or access to partially or fully matching cord blood from a sibling.
The expanded access protocol is in addition to a phase II trial currently underway but no longer recruiting.
Dr. Joanne Kurtzberg nicely sums up the hope that lies in cord blood to treat autism and so much more:
"The cord blood journey is 27 years young. We know how to bank cord blood better than we used to. We can manipulate in ways we couldn't in the past, and I think that the use of cord blood in cell therapies and regenerative medicine as an emerging field now has enormous potential and will be one of the true big advances in the next ten years."
Parents who have cord blood stored with Cryo-Cell and want to learn more about gaining access to these trials treating autism can use the link to make contact with us.